Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines

Journal of Immunology

Volumn 185, Issue 12, 2010, Pages 7583-7595

  Draper, Simon J ^a   Biswas, Sumi ^a   Spencer, Alexandra J ^a   Remarque, Edmond J ^b   Capone, Stefania ^c   Naddeo, Mariarosaria ^c   Dicks, Matthew D J ^a   Faber, Bart W ^b   De Cassan, Simone C ^a   Folgori, Antonella ^c   Nicosia, Alfredo ^c   Gilbert, Sarah C ^a   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^c Okairòs AG ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM HYDROXIDE; CHIMPANZEE ADENOVIRUS 63; COVACCINE; IMMUNOGLOBULIN G; MALARIA VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; MALARIA CONTROL; MEMORY CELL; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINE PRODUCTION;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; MACACA MULATTA; MALARIA VACCINES; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; MICE; PLASMODIUM FALCIPARUM; POXVIRIDAE; PROTOZOAN PROTEINS; VACCINES, SUBUNIT; VACCINIA VIRUS;

EID: 78650655421     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001760     Document Type: Article

References (70)

1. Okiro, E. A., S. I. Hay, P. W. Gikandi, S. K. Sharif, A. M. Noor, N. Peshu, K. Marsh, and R. W. Snow. 2007. The decline in paediatric malaria admissions on the coast of Kenya. Malar. J. 6:151.
2. M. Aregawi, R. E. Cibulskis, M. Otten, R. Williams, and WHO Global Malaria Programme. Surveillance Monitoring and Evaluation Unit. 2009. World Malaria Report 2009. World Health Organization, Geneva, Switzerland.
3. Greenwood, B., and G. Targett. 2009. Do we still need a malaria vaccine? Parasite Immunol. 31:582-586.
4. Goodman, A. L., and S. J. Draper. 2010. Blood-stage malaria vaccines - recent progress and future challenges. Ann. Trop. Med. Parasitol. 104:189-211.
5. Holder, A. A. 2009. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 136:1445-1456.
6. Remarque, E. J., B. W. Faber, C. H. Kocken, and A. W. Thomas. 2008. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 24:74-84.
7. Hill, A. V., A. Reyes-Sandoval, G. A. O'Hara, K. Ewer, A. Lawrie, A. L. Goodman, A. Nicosia, A. Folgori, S. Colloca, R. Cortese, et al. 2010. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 6:78-83.
8. Draper, S. J., and J. L. Heeney. 2010. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8:62-73.
9. Draper, S. J., A. C. Moore, A. L. Goodman, C. A. Long, A. A. Holder, S. C. Gilbert, F. Hill, and A. V. Hill. 2008. Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med. 14:819-821.
10. Bruder, J. T., M. E. Stefaniak, N. B. Patterson, P. Chen, S. Konovalova, K. Limbach, J. J. Campo, D. Ettyreddy, S. Li, F. Dubovsky, et al. 2010. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine 28:3201-3210.
11. Goodman, A. L., C. Epp, D. Moss, A. A. Holder, J. M. Wilson, G. P. Gao, C. A. Long, E. J. Remarque, A. W. Thomas, V. Ammendola, et al. 2010. New candidate vaccines against blood-stage P. falciparum malaria: Prime-boost immunization regimes incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on MSP-1. Infect. Immun. 78:4601-4612.
12. Draper, S. J., A. L. Goodman, S. Biswas, E. K. Forbes, A. C. Moore, S. C. Gilbert, and A. V. Hill. 2009. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody-and T cell-mediated multistage protection against malaria. Cell Host Microbe 5:95-105.
13. Xu, H., A. N. Hodder, H. Yan, P. E. Crewther, R. F. Anders, and M. F. Good. 2000. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. J. Immunol. 165:389-396.
14. Langhorne, J., F. M. Ndungu, A. M. Sponaas, and K. Marsh. 2008. Immunity to malaria: more questions than answers. Nat. Immunol. 9:725-732.
15. Fowkes, F. J., J. S. Richards, J. A. Simpson, and J. G. Beeson. 2010. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med. 7: e1000218.
16. Stanisic, D. I., J. S. Richards, F. J. McCallum, P. Michon, C. L. King, S. Schoepflin, P. R. Gilson, V. J. Murphy, R. F. Anders, I. Mueller, and J. G. Beeson. 2009. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect. Immun. 77:1165-1174.
17. Pombo, D. J., G. Lawrence, C. Hirunpetcharat, C. Rzepczyk, M. Bryden, N. Cloonan, K. Anderson, Y. Mahakunkijcharoen, L. B. Martin, D. Wilson, et al. 2002. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360:610-617.
18. Riley, E. M., S. J. Allen, J. G. Wheeler, M. J. Blackman, S. Bennett, B. Takacs, H. J. Schönfeld, A. A. Holder, and B. M. Greenwood. 1992. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol. 14:321-337.
19. Roestenberg, M., M. McCall, J. Hopman, J. Wiersma, A. J. Luty, G. J. van Gemert, M. van de Vegte-Bolmer, B. van Schaijk, K. Teelen, T. Arens, et al. 2009. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361:468-477.
20. Pinzon-Charry, A., V. McPhun, V. Kienzle, C. Hirunpetcharat, C. Engwerda, J. McCarthy, and M. F. Good. 2010. Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. J. Clin. Invest. 120:2967-2978.
21. Robinson, L. J., M. C. D'Ombrain, D. I. Stanisic, J. Taraika, N. Bernard, J. S. Richards, J. G. Beeson, L. Tavul, P. Michon, I. Mueller, and L. Schofield. 2009. Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea. Infect. Immun. 77:3033-3043.
22. Joos, C., L. Marrama, H. E. Polson, S. Corre, A. M. Diatta, B. Diouf, J. F. Trape, A. Tall, S. Longacre, and R. Perraut. 2010. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS ONE 5: e9871.
23. Bouharoun-Tayoun, H., P. Attanath, A. Sabchareon, T. Chongsuphajaisiddhi, and P. Druilhe. 1990. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 172:1633-1641.
24. Walther, M., J. Woodruff, F. Edele, D. Jeffries, J. E. Tongren, E. King, L. Andrews, P. Bejon, S. C. Gilbert, J. B. De Souza, et al. 2006. Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. J. Immunol. 177:5736-5745.
25. Finney, O. C., E. M. Riley, and M. Walther. 2010. Regulatory T cells in malaria-friend or foe? Trends Immunol. 31:63-70.
26. Wipasa, J., H. Xu, A. Stowers, and M. F. Good. 2001. Apoptotic deletion of Th cells specific for the 19-kDa carboxyl-terminal fragment of merozoite surface protein 1 during malaria infection. J. Immunol. 167:3903-3909.
27. Weiss, G. E., P. D. Crompton, S. Li, L. A. Walsh, S. Moir, B. Traore, K. Kayentao, A. Ongoiba, O. K. Doumbo, and S. K. Pierce. 2009. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J. Immunol. 183:2176-2182.
28. Wykes, M. N., Y. H. Zhou, X. Q. Liu, and M. F. Good. 2005. Plasmodium yoelii can ablate vaccine-induced long-term protection in mice. J. Immunol. 175:2510-2516.
29. Murhandarwati, E. E., L. Wang, H. D. de Silva, C. Ma, M. Plebanski, C. G. Black, and R. L. Coppel. 2010. Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection. Infect. Immun. 78:680-687.
30. Crompton, P. D., K. Miura, B. Traore, K. Kayentao, A. Ongoiba, G. Weiss, S. Doumbo, D. Doumtabe, Y. Kone, C. Y. Huang, et al. 2010. In vitro growthinhibitory activity and malaria risk in a cohort study in mali. Infect. Immun. 78:737-745.
31. Douglas, A. D., S. C. de Cassan, M. D. J. Dicks, S. C. Gilbert, A. V. S. Hill, and S. J. Draper. 2010. Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against P. falciparum MSP1. Vaccine 28:7167-7178.
32. Gómez-Román, V. R., R. H. Florese, B. Peng, D. C. Montefiori, V. S. Kalyanaraman, D. Venzon, I. Srivastava, S. W. Barnett, and M. Robert-Guroff. 2006. An adenovirusbased HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J. Acquir. Immune Defic. Syndr. 43:270-277.
33. Vinner, L., D. Therrien, E. Wee, I. Laursen, T. Hanke, S. L. Corbet, and A. Fomsgaard. 2006. Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1. APMIS 114:690-699.
34. Shu, Y., S. Winfrey, Z. Y. Yang, L. Xu, S. S. Rao, I. Srivastava, S. W. Barnett, G. J. Nabel, and J. R. Mascola. 2007. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25:1398-1408.
35. Zolla-Pazner, S., M. Lubeck, S. Xu, S. Burda, R. J. Natuk, F. Sinangil, K. Steimer, R. C. Gallo, J. W. Eichberg, T. Matthews, and M. Robert-Guroff. 1998. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J. Virol. 72:1052-1059.
36. Patterson, L. J., N. Malkevitch, J. Pinczewski, D. Venzon, Y. Lou, B. Peng, C. Munch, M. Leonard, E. Richardson, K. Aldrich, et al. 2003. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J. Virol. 77:8607-8620.
37. Stewart, V. A., S. M. McGrath, P. M. Dubois, M. G. Pau, P. Mettens, J. Shott, M. Cobb, J. R. Burge, D. Larson, L. A. Ware, et al. 2007. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS, S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75:2283-2290.
38. Hutchings, C. L., A. J. Birkett, A. C. Moore, and A. V. Hill. 2007. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect. Immun. 75:5819-5826.
39. Hilgers, L. A., and A. G. Blom. 2006. Sucrose fatty acid sulphate esters as novel vaccine adjuvant. Vaccine 24 (Suppl. 2): S2-81-82.
40. Kennedy, M. C., J. Wang, Y. Zhang, A. P. Miles, F. Chitsaz, A. Saul, C. A. Long, L. H. Miller, and A. W. Stowers. 2002. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. 70:6948-6960.
41. Kusi, K. A., B. W. Faber, A. W. Thomas, and E. J. Remarque. 2009. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS ONE 4: e8110.
42. Quelhas, D., L. Puyol, L. Quintó, E. Serra-Casas, T. Nhampossa, E. Macete, P. Aide, A. Mayor, I. Mandomando, S. Sanz, et al. 2008. Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique. Clin. Vaccine Immunol. 15:1282-1291.
43. Pizarro, J. C., B. Vulliez-Le Normand, M. L. Chesne-Seck, C. R. Collins, C. Withers-Martinez, F. Hackett, M. J. Blackman, B. W. Faber, E. J. Remarque, C. H. Kocken, et al. 2005. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science 308:408-411.
44. Aste-Amézaga, M., A. J. Bett, F. Wang, D. R. Casimiro, J. M. Antonello, D. K. Patel, E. C. Dell, L. L. Franlin, N. M. Dougherty, P. S. Bennett, et al. 2004. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum. Gene Ther. 15:293-304.
45. Liu, J., B. A. Ewald, D. M. Lynch, M. Denholtz, P. Abbink, A. A. Lemckert, A. Carville, K. G. Mansfield, M. J. Havenga, J. Goudsmit, and D. H. Barouch. 2008. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82:4844-4852.
46. Liu, J., K. L. O'Brien, D. M. Lynch, N. L. Simmons, A. La Porte, A. M. Riggs, P. Abbink, R. T. Coffey, L. E. Grandpre, M. S. Seaman, et al. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91.
47. Pitcher, C. J., S. I. Hagen, J. M. Walker, R. Lum, B. L. Mitchell, V. C. Maino, M. K. Axthelm, and L. J. Picker. 2002. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168:29-43.
48. Ruiz, W., W. L. McClements, K. U. Jansen, and M. T. Esser. 2005. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J. Immune Based Ther. Vaccines 3:2.
49. Cornelius, C. A., L. E. Quenee, K. A. Overheim, F. Koster, T. L. Brasel, D. Elli, N. A. Ciletti, and O. Schneewind. 2008. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect. Immun. 76:5588-5597.
50. Miura, K., H. Zhou, A. Diouf, S. E. Moretz, M. P. Fay, L. H. Miller, L. B. Martin, M. A. Pierce, R. D. Ellis, G. E. Mullen, and C. A. Long. 2009. Anti-apicalmembrane-antigen-1 antibody is more effective than anti-42-kilodaltonmerozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin. Vaccine Immunol. 16:963-968.
51. Roestenberg, M., E. Remarque, E. de Jonge, R. Hermsen, H. Blythman, O. Leroy, E. Imoukhuede, S. Jepsen, O. Ofori-Anyinam, B. Faber, et al. 2008. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS ONE 3: e3960.
52. Hutnick, N. A., D. Carnathan, K. Demers, G. Makedonas, H. C. Ertl, and M. R. Betts. 2010. Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine 28:1932-1941.
53. Reyes-Sandoval, A., T. Berthoud, N. Alder, L. Siani, S. C. Gilbert, A. Nicosia, S. Colloca, R. Cortese, and A. V. Hill. 2010. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect. Immun. 78:145-153.
54. Lamoreaux, L., M. Roederer, and R. Koup. 2006. Intracellular cytokine optimization and standard operating procedure. Nat. Protoc. 1:1507-1516.
55. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850.
56. Seder, R. A., P. A. Darrah, and M. Roederer. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8:247-258.
57. Xiang, Z., G. Gao, A. Reyes-Sandoval, C. J. Cohen, Y. Li, J. M. Bergelson, J. M. Wilson, and H. C. Ertl. 2002. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76:2667-2675.
58. Coler, R. N., D. Carter, M. Friede, and S. G. Reed. 2009. Adjuvants for malaria vaccines. Parasite Immunol. 31:520-528.
59. Miura, K., H. Zhou, O. V. Muratova, A. C. Orcutt, B. Giersing, L. H. Miller, and C. A. Long. 2007. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect. Immun. 75:5827-5836.
60. Bouharoun-Tayoun, H., and P. Druilhe. 1992. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect. Immun. 60:1473-1481.
61. McIntosh, R. S., J. Shi, R. M. Jennings, J. C. Chappel, T. F. de Koning-Ward, T. Smith, J. Green, M. van Egmond, J. H. Leusen, M. Lazarou, et al. 2007. The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog. 3: e72.
62. Blanchard Rohner, G., M. D. Snape, D. F. Kelly, T. John, A. Morant, L. M. Yu, A. Borkowski, F. Ceddia, R. Borrow, C. A. Siegrist, and A. J. Pollard. 2008. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J. Immunol. 180:2165-2173.
63. Crompton, P. D., M. Mircetic, G. Weiss, A. Baughman, C. Y. Huang, D. J. Topham, J. J. Treanor, I. Sanz, F. E. Lee, A. P. Durbin, et al. 2009. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J. Immunol. 182:3318-3326.
64. Mamani-Matsuda, M., A. Cosma, S. Weller, A. Faili, C. Staib, L. Garçon, O. Hermine, O. Beyne-Rauzy, C. Fieschi, J. O. Pers, et al. 2008. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 111:4653-4659.
65. Nanan, R., D. Heinrich, M. Frosch, and H. W. Kreth. 2001. Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. Vaccine 20:498-504.
66. Leyendeckers, H., M. Odendahl, A. Löhndorf, J. Irsch, M. Spangfort, S. Miltenyi, N. Hunzelmann, M. Assenmacher, A. Radbruch, and J. Schmitz. 1999. Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur. J. Immunol. 29:1406-1417.
67. Ndungu, F. M., E. T. Cadman, J. Coulcher, E. Nduati, E. Couper, D. W. Macdonald, D. Ng, and J. Langhorne. 2009. Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice. PLoS Pathog. 5: e1000690.
68. Traore, B., Y. Koné, S. Doumbo, D. Doumtabé, A. Traoré, P. D. Crompton, M. Mircetic, C. Y. Huang, K. Kayentao, A. Dicko, et al. 2009. The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine 27:7299-7303.
69. Esen, M., P. G. Kremsner, R. Schleucher, M. Gässler, E. B. Imoukhuede, N. Imbault, O. Leroy, S. Jepsen, B. W. Knudsen, M. Schumm, et al. 2009. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 27:6862-6868.
70. Moorthy, V. S., E. B. Imoukhuede, S. Keating, M. Pinder, D. Webster, M. A. Skinner, S. C. Gilbert, G. Walraven, and A. V. Hill. 2004. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189:2213-2219.